

VEGA DAILY

Unlock Your Best Quote
Ask VEGA Now!

November 18, 2025

VITAMIN

01

It is reported that as of November 17, Tianxin Pharmaceutical has suspended external quotations and order signing for folic acid, placing the market in a temporary quiet phase and drawing increased attention.

AMINO ACID

02

Recently, the lysine market has shown a weaker tone. Producer quotations have edged slightly lower with stable supply, yet transactions remain limited as end-users resist replenishing. The short-term outlook remains soft, with market attention focused on upcoming order intake from manufacturers.

API

03

- The lincomycin HCl market continues to face ample supply, and new production capacity has intensified the supply-demand imbalance, pushing prices further downward. Current mainstream prices stand at USD 48.61–51.1/BOU, with continued downward pressure expected in the short term.
- Meanwhile, Pfizer Inc. announced the completion of its acquisition of Metsera, a biopharmaceutical company focused on developing next-generation therapies for obesity and cardiometabolic diseases. The deal includes USD 65.60 per share in cash (enterprise value approx. USD 7 billion) plus up to USD 20.65 per share in contingent value rights (CVRs), totaling up to USD 2.2 billion, tied to specific clinical and regulatory milestones. The total transaction value is approximately USD 9.2 billion. Following completion, Metsera becomes a wholly owned subsidiary of Pfizer, and its common stock has ceased trading on the Nasdaq Global Select Market.

FOOD ADDITIVE

04

Creatine monohydrate in the nutrition enhancer segment remains stable due to raw-material and market factors. Current factory quotations stand at USD 3–3.12/KG with delivery schedules pushed into December, and future price increases cannot be ruled out.

Reported by Candice, Shea and Sharon

ONE STOP SOLUTION SUPPLIER



www.vegapharma.com



www.vegafeed.com



www.prumix.com

